AP70 / Aprogen - LARVOL DELTA

Aprogen develops CD47 bispecific antibody with improved cancer cell specific binding ability [Google translation] (HIT News) - "Aprogen...announced on the 9th that they had developed a 'CD47 bispecific antibody' with significantly improved cancer cell-specific binding ability. According to the company, the CD47 bispecific antibody developed this time adheres 1879 times and 962 times better to cancer cells, 'CEM7' and 'NALM6', respectively, than to red blood cells within the cell tests conducted by the company itself. The company explains that it is up to 1,000 times higher than Gilead Sciences' Magrolimab, which showed 1.87 and 6.8 times the results in the same experiment, respectively."

New molecule • Oncology